Nouress is a drug owned by Baxter Healthcare Corp. It is protected by 19 US drug patents filed from 2020 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 15, 2039. Details of Nouress's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11045438 | Cysteine composition and injection |
Mar, 2039
(13 years from now) | Active |
| US10702490 | Cysteine composition and injection |
Mar, 2039
(13 years from now) | Active |
| US10543186 | Cysteine composition and injection |
Mar, 2039
(13 years from now) | Active |
| US10493051 | Cysteine composition and injection |
Mar, 2039
(13 years from now) | Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Mar, 2039
(13 years from now) | Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nouress's patents.
Latest Legal Activities on Nouress's Patents
Given below is the list of recent legal activities going on the following patents of Nouress.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail O.P. Petition Decision | 29 Dec, 2023 | US10702490 |
| Email Notification Critical | 29 Dec, 2023 | US10702490 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 26 Dec, 2023 | US10702490 |
| Record Petition Decision of Granted to Make Entity Status large | 22 Dec, 2023 | US10702490 |
| O.P. Petition Decision | 22 Dec, 2023 | US10702490 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Nov, 2023 | US10653719 |
| Payment of Maintenance Fee under 1.28(c) | 16 Oct, 2023 | US10702490 |
| Petition Entered | 16 Oct, 2023 | US10702490 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Oct, 2023 | US10702490 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Oct, 2023 | US10702490 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Nouress and ongoing litigations to help you estimate the early arrival of Nouress generic.
Nouress's Litigations
Nouress been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 19, 2020, against patent number US10478453. The petitioner Eton Pharmaceuticals, Inc., challenged the validity of this patent, with Exela Pharma Sciences, LLC as the respondent. Click below to track the latest information on how companies are challenging Nouress's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11642370 | February, 2024 |
Institution Denied
(08 Aug, 2024) | Exela Pharma Sciences, LLC | Nexus Pharmaceuticals LLC |
| US10653719 | September, 2020 |
Institution Denied
(23 Apr, 2021) | Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 |
Terminated-Denied
(15 Dec, 2020) | Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 |
Institution Denied
(18 Nov, 2020) | Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
US patents provide insights into the exclusivity only within the United States, but Nouress is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nouress's family patents as well as insights into ongoing legal events on those patents.
Nouress's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Nouress's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 15, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nouress Generic API suppliers:
Cysteine Hydrochloride is the generic name for the brand Nouress. 2 different companies have already filed for the generic of Nouress, with Dr Reddys Labs Sa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Nouress's generic
Alternative Brands for Nouress
Nouress which is used for treating patients needing parenteral nutrition through intravenous administration of a diluted cysteine hydrochloride solution., has several other brand drugs in the same treatment category and using the same active ingredient (Cysteine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Exela Pharma |
| |||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cysteine Hydrochloride, Nouress's active ingredient. Check the complete list of approved generic manufacturers for Nouress
About Nouress
Nouress is a drug owned by Baxter Healthcare Corp. It is used for treating patients needing parenteral nutrition through intravenous administration of a diluted cysteine hydrochloride solution. Nouress uses Cysteine Hydrochloride as an active ingredient. Nouress was launched by Baxter Hlthcare Corp in 2019.
Approval Date:
Nouress was approved by FDA for market use on 13 December, 2019.
Active Ingredient:
Nouress uses Cysteine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Cysteine Hydrochloride ingredient
Treatment:
Nouress is used for treating patients needing parenteral nutrition through intravenous administration of a diluted cysteine hydrochloride solution.
Dosage:
Nouress is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG/10ML (50MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |